Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Viking Therapeutics Inc’s stock clocked out at $35.42, up 0.68% from its previous closing price of $35.18. In other words, the price has increased by $0.68 from its previous closing price. On the day, 1.84 million shares were traded. VKTX stock price reached its highest trading level at $36.1746 during the session, while it also had its lowest trading level at $34.8811.
Ratios:
To gain a deeper understanding of VKTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 28.34 and its Current Ratio is at 28.34. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Canaccord Genuity on October 29, 2025, initiated with a Buy rating and assigned the stock a target price of $106.
On April 29, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $104.
On April 08, 2025, Goldman started tracking the stock assigning a Neutral rating and target price of $30.Goldman initiated its Neutral rating on April 08, 2025, with a $30 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 02 ’26 when MATTHEW W. FOEHR bought 16,000 shares for $35.11 per share.
Mancini Marianna sold 6,185 shares of VKTX for $216,492 on Oct 28 ’25. The Chief Operating Officer now owns 382,467 shares after completing the transaction at $35.00 per share. On Oct 27 ’25, another insider, Rowland Charles A Jr, who serves as the Director of the company, sold 60,000 shares for $35.57 each. As a result, the insider received 2,134,278 and left with 30,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VKTX now has a Market Capitalization of 4003747072 and an Enterprise Value of 3289932288.
Stock Price History:
The Beta on a monthly basis for VKTX is 0.70, which has changed by -0.16717613 over the last 52 weeks, in comparison to a change of 0.14778805 over the same period for the S&P500. Over the past 52 weeks, VKTX has reached a high of $43.55, while it has fallen to a 52-week low of $18.92. The 50-Day Moving Average of the stock is -2.49%, while the 200-Day Moving Average is calculated to be 16.30%.
Shares Statistics:
It appears that VKTX traded 3.73M shares on average per day over the past three months and 2077530 shares per day over the past ten days. A total of 112.45M shares are outstanding, with a floating share count of 109.84M. Insiders hold about 2.83% of the company’s shares, while institutions hold 65.27% stake in the company. Shares short for VKTX as of 1765756800 were 24029319 with a Short Ratio of 6.45, compared to 1763078400 on 24785654. Therefore, it implies a Short% of Shares Outstanding of 24029319 and a Short% of Float of 25.480000000000004.
Earnings Estimates
The stock of Viking Therapeutics Inc (VKTX) is currently being evaluated by 14.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.94, with high estimates of -$0.76 and low estimates of -$1.19.
Analysts are recommending an EPS of between -$2.07 and -$2.87 for the fiscal current year, implying an average EPS of -$2.61. EPS for the following year is -$3.72, with 13.0 analysts recommending between -$3.13 and -$4.94.
